Ipsen S.A. (LON:0MH6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
90.70
-4.79 (-5.02%)
At close: Apr 17, 2025
-16.00%
Market Cap 6.49B
Revenue (ttm) 2.96B
Net Income (ttm) 286.05M
Shares Out n/a
EPS (ttm) 3.43
PE Ratio 22.70
Forward PE n/a
Dividend 1.02 (1.13%)
Ex-Dividend Date Jun 4, 2025
Volume 102,727
Average Volume 67,105
Open 94.05
Previous Close 95.49
Day's Range 90.40 - 92.80
52-Week Range 82.42 - 104.61
Beta 0.40
RSI 33.01
Earnings Date Jul 31, 2025

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange London Stock Exchange
Ticker Symbol 0MH6
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.